Bahram Valamehr - Dec 13, 2021 Form 4 Insider Report for FATE THERAPEUTICS INC (FATE)

Role
Chief R&D Officer
Signature
/s/ Cindy Tahl, as Attorney-in-Fact
Stock symbol
FATE
Transactions as of
Dec 13, 2021
Transactions value $
-$1,123,156
Form type
4
Date filed
12/14/2021, 03:18 PM
Previous filing
Nov 22, 2021
Next filing
Jan 12, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FATE Common Stock Options Exercise $68.3K +25K +15.95% $2.73 182K Dec 13, 2021 Direct F1
transaction FATE Common Stock Sale -$95.9K -2.1K -1.16% $45.68* 180K Dec 13, 2021 Direct F1, F2
transaction FATE Common Stock Sale -$328K -7.02K -3.91% $46.72* 173K Dec 13, 2021 Direct F1, F3
transaction FATE Common Stock Sale -$313K -6.56K -3.8% $47.61* 166K Dec 13, 2021 Direct F1, F4
transaction FATE Common Stock Sale -$376K -7.72K -4.65% $48.75* 158K Dec 13, 2021 Direct F1, F5
transaction FATE Common Stock Sale -$78.8K -1.6K -1.01% $49.27* 157K Dec 13, 2021 Direct F1, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FATE Stock Option (Right to Buy) Options Exercise $0 +25K +69.14% $0.00 61.2K Dec 13, 2021 Common Stock 25K $2.73 Direct F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020.
F2 Represents the weighted average sale price of the shares sold from $45.18 to $46.17 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of he Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 6.
F3 Represents the weighted average sale price of the shares sold from $46.20 to $47.17 per share.
F4 Represents the weighted average sale price of the shares sold from $47.21 to $48.20 per share.
F5 Represents the weighted average sale price of the shares sold from $48.21 to $49.20 per share.
F6 Represents the weighted average sale price of the shares sold from $49.21 to $49.40 per share.
F7 This option is fully vested.